All In Biotech

Drug Trial Radar · NCT05853367

Study of MK-0472 in Participants With Advanced/Metastatic Solid Tumors (MK-0472-001)

A Phase 1/1b Open-label, Multicenter Clinical Study of MK-0472 as Monotherapy and Combination Therapy in Participants With Advanced/Metastatic Solid Tumors.

Last checked: Nov 19, 2026Latest source record: Aug 7, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

95

Actual

Start

Jul 6, 2023

Primary completion

Jun 24, 2028

Study completion Jun 24, 2028

Sponsor

Lead sponsor
Merck Sharp & Dohme LLCMerck & Co. (MRK)
Sponsor type
Industry
First posted
May 10, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to assess the efficacy, safety, and tolerability of MK-0472 administered as monotherapy and in combination with pembrolizumab (MK-3475) or MK-1084 in participants with histologically or cytologically confirmed diagnosis of advanced/metastatic solid tumors.

Conditions

  • Metastatic Solid Tumors
  • Advanced Solid Tumors

Interventions

  • MK-0472Drug

    Oral Administration

  • PembrolizumabBiological

    IV infusion

  • MK-1084Drug

    Oral Administration

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants Who Experience a Dose Limiting Toxicity (DLT) as Assessed Using Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0Time frame: At the end of Cycle 1 (each cycle is 21 days)
  2. Number of Participants Who Experience One or More Adverse Events (AEs)Time frame: Up to approximately 60 months
  3. Number of Participants Who Discontinue Study Treatment Due to an Adverse Event (AE)Time frame: Up to approximately 60 months

Locations

25 sites in 7 countries. Site status is shown where the registry gives one.

  • Northwestern Memorial Hospital ( Site 0002)

    Chicago, Illinois

  • The University of Louisville, James Graham Brown Cancer Center ( Site 0004)

    Louisville, Kentucky

  • John Theurer Cancer Center at Hackensack University Medical Center ( Site 0001)

    Hackensack, New Jersey

  • Rutgers Cancer Institute of New Jersey ( Site 0005)

    New Brunswick, New Jersey

  • Princess Margaret Cancer Centre ( Site 0101)

    Toronto, Ontario, Canada

  • Centre Hospitalier de l'Université de Montréal-Unit for Innovative Therapies ( Site 0100)

    Montreal, Quebec, Canada

  • Département clinique de médecine de laboratoire du CHUM ( Site 0104)

    Montreal, Quebec, Canada

  • Centro de Estudios Clínicos SAGA ( Site 0701)

    Santiago, Region M. de Santiago, Chile

  • Fundacion Arturo Lopez Perez ( Site 0700)

    Santiago, Region M. de Santiago, Chile

  • Centro de Investigacion Clinicadela Universidad Catolica ( Site 0703)

    Santiago, Region M. de Santiago, Chile

  • Bradfordhill ( Site 0702)

    Santiago, Region M. de Santiago, Chile

  • Rambam Health Care Campus ( Site 0304)

    Haifa, Israel

  • Shaare Zedek Medical Center ( Site 0303)

    Jerusalem, Israel

  • Rabin Medical Center ( Site 0301)

    Petah Tikva, Israel

  • Sheba Medical Center ( Site 0300)

    Ramat Gan, Israel

  • Sourasky Medical Center ( Site 0302)

    Tel Aviv, Israel

  • Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - Panstwowy Instytut Badawczy w Warszawie ( Site 0401)

    Warsaw, Masovian Voivodeship, Poland

  • Uniwersyteckie Centrum Kliniczne ( Site 0400)

    Gdansk, Pomeranian Voivodeship, Poland

  • Hospital Universitari Vall d'Hebron ( Site 0500)

    Barcelona, Spain

  • Hospital Virgen del Rocio ( Site 0503)

    Seville, Spain

  • Institut Català d'Oncologia - L'Hospitalet-Medical Oncology ( Site 0501)

    L'Hospitalet de Llobregat, Catalonia, Spain

  • Centro Integral Oncologico Clara Campal-Hospital HM Universitario Sanchinarro-START Madrid, ( Site 0504)

    Madrid, Madrid, Comunidad de, Spain

  • Hôpitaux Universitaires de Genève (HUG) ( Site 0202)

    Geneva, Canton of Geneva, Switzerland

  • Cantonal Hospital St.Gallen-Oncology & Hematology ( Site 0201)

    Sankt Gallen, Canton of St. Gallen, Switzerland

  • Ospedale Regionale Bellinzona e Valli ( Site 0200)

    Bellinzona, Canton Ticino, Switzerland

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.